Back to Authors

Gubens, Matthew A.

https://orcid.org/0000-0002-6482-1954

A5055548058 | I4210167126

Mayo Clinic

UCSF Helen Diller Family Comprehensive Cancer Center

Citations 13

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472

10.6004/jnccn.2019.0059 | PMID 31805526

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8007-8007

10.1200/jco.2014.32.15_suppl.8007

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9024-9024

10.1200/jco.2016.34.15_suppl.9024